Related Experiment Video

Updated: Nov 5, 2025

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

5.8K

The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target

Michael F Sharp1, Rohan Bythell-Douglas1, Andrew J Deans2

  • 1Genome Stability Unit, St. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.

Molecular Cell
|May 13, 2021
PubMed

Insights

Targeting the Fanconi anemia (FA) pathway offers a novel cancer therapy. Inhibiting the FA core complex selectively kills cancer cells, providing a less toxic alternative to chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chemotherapy causes severe side effects due to indiscriminate DNA damage in healthy and cancerous cells.
  • DNA repair pathway inhibition presents a targeted and less toxic cancer treatment strategy.
  • The Fanconi anemia (FA) E3 ligase core complex plays a crucial role in DNA lesion repair.

Purpose of the Study:

  • To evaluate the Fanconi anemia (FA) core complex as a drug target for cancer therapy.
  • To review genetic and biochemical evidence supporting the FA core complex as a viable therapeutic target.
  • To discuss data that can accelerate the clinical application of FA core complex inhibitors.

Main Methods:

  • Review of genetic evidence for FA pathway's role in cancer cell death.
  • Analysis of biochemical data on FA core complex function in DNA repair.
  • Examination of structural data for inhibitor development.

Main Results:

  • Inactivation of the FA pathway selectively eliminates cancer cells, particularly those deficient in BRCA1, BRCA2, or ATM.
  • The FA core complex is essential for efficient removal of specific DNA lesions.
  • Genetic and biochemical studies strongly support the FA core complex as a druggable target.

Conclusions:

  • The Fanconi anemia (FA) core complex is a promising target for developing novel cancer therapeutics.
  • Inhibiting the FA pathway offers a targeted approach to cancer treatment with potentially reduced toxicity.
  • Further research into FA core complex inhibitors can expedite clinical translation for cancer therapy.

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

6.1K
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.8K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K